David Misdrahi
Hospital Practitionner
/ Contact
+33 5 57 57 15 51
www.orcid.org/0000-0003-1146-3206
/ Address of work
INCIA - UMR 5287 - CNRS/Université de Bordeaux - Zone nord Bat 2 - 2e étage, 146, rue Léo-Saignat - 33076 Bordeaux cedex
Scientific articles
-
Identifying the role of (dis)inhibition in the vicious cycle of substance use through ecological momentary assessment and resting-state fMRI
Transl Psychiatry. 2024-06-19. 14(1)
10.1038/s41398-024-02949-1 -
Multi‐level prediction of substance use: Interaction of white matter integrity, resting‐state connectivity and inhibitory control measured repeatedly in every‐day life
Addiction Biology. 2024-05-01. 29(5)
10.1111/adb.13400 -
Craving dynamics and related cerebral substrates predict timing of use in alcohol, tobacco, and cannabis use disorders
Addiction Neuroscience. 2023-12-01. 9 : 100138.
10.1016/j.addicn.2023.100138 -
Predictors of medication adherence in a large 1-year prospective cohort of individuals with schizophrenia: insights from the multicentric FACE-SZ dataset
Transl Psychiatry. 2023-11-07. 13(1)
10.1038/s41398-023-02640-x -
Family psychoeducation to improve outcome in caregivers and patients with schizophrenia: a randomized clinical trial
Front. Psychiatry. 2023-06-23. 14
10.3389/fpsyt.2023.1171661 -
Clinical and pharmacological correlates of caffeine consumption in subjects with schizophrenia – Data from the FACE-SZ cohort.
Journal of Psychiatric Research. 2023-05-01. 161 : 206-212.
10.1016/j.jpsychires.2023.03.017 -
Relationships between neuropsychological performance, insight, medication adherence, and social metacognition in schizophrenia.
Schizophrenia Research. 2023-02-01. 252 : 48-55.
10.1016/j.schres.2022.12.037 -
3-year incidence and predictors of metabolic syndrome in schizophrenia in the national FACE-SZ cohort.
Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2023-01-01. 120 : 110641.
10.1016/j.pnpbp.2022.110641 -
Mood Variability, Craving, and Substance Use Disorders: From Intrinsic Brain Network Connectivity to Daily Life Experience
Biological Psychiatry: Cognitive Neuroscience and Neuroimaging. 2022-11-01.
10.1016/j.bpsc.2022.11.002 -
The Executive Functioning Paradox in Substance Use Disorders
Biomedicines. 2022-10-28. 10(11) : 2728.
10.3390/biomedicines10112728 -
The impact of parent history of severe mental illness on schizophrenia outcomes: results from the real-world FACE-SZ cohort.
Eur Arch Psychiatry Clin Neurosci. 2022-07-19. 273(4) : 825-837.
10.1007/s00406-022-01449-x -
Recommendations of the Schizophrenia Expert Center network for adequate physical activity in real-world schizophrenia (FACE-SZ).
Eur Arch Psychiatry Clin Neurosci. 2022-04-20. 272(7) : 1273-1282.
10.1007/s00406-022-01384-x -
Early-life factors associated with increased risk of disability pension in the national real-world schizophrenia FACE-SZ cohort study.
Eur Arch Psychiatry Clin Neurosci. 2022-03-25. 272(7) : 1379-1384.
10.1007/s00406-021-01364-7 -
Relationship between neurocognition and theory of mind as a function of symptomatic profile in schizophrenia: results from the national FACE-SZ cohort.
Cognitive Neuropsychiatry. 2021-12-09. 27(1) : 49-68.
10.1080/13546805.2021.2011184 -
Redefining peripheral inflammation signature in schizophrenia based on the real-world FACE-SZ cohort.
Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2021-12-01. 111 : 110335.
10.1016/j.pnpbp.2021.110335 -
Comparison of three scales (BIS, SUMD and BCIS) for measuring insight dimensions and their evolution after one-year of follow-up: Findings from the FACE-SZ Cohort.
Psychiatry Research. 2021-09-01. 303 : 114044.
10.1016/j.psychres.2021.114044 -
Recommendations of the schizophrenia expert center network for the screening prevention and treatment of sleep disorders based on the results from the real-world schizophrenia FACE-SZ national cohort.
Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2021-08-01. 110 : 110275.
10.1016/j.pnpbp.2021.110275 -
A conceptual framework to develop a patient-reported experience measure of the quality of mental health care: a qualitative study of the PREMIUM project in France.
Journal of Market Access & Health Policy. 2021-01-01. 9(1)
10.1080/20016689.2021.1885789 -
Major depression, sleep, hostility and body mass index are associated with impaired quality of life in schizophrenia. Results from the FACE-SZ cohort.
Journal of Affective Disorders. 2020-09-01. 274 : 617-623.
10.1016/j.jad.2020.05.003 -
Brief interventions for improving adherence in schizophrenia: A pilot study using electronic medication event monitoring
Psychiatry Research. 2020-03-01. 285 : 112780.
10.1016/j.psychres.2020.112780 -
Early and very early-onset schizophrenia compared with adult-onset schizophrenia: French FACE-SZ database
Brain Behav. 2020-01-07. 10(2)
10.1002/brb3.1495 -
Assessing metacognitive and help-seeking strategies in schizophrenia: design and psychometric validation of the Versailles Metacognitive Strategies Evaluation Questionnaire
Clin Rehabil. 2019-12-04. 34(2) : 263-275.
10.1177/0269215519888784 -
Confirmation of a Two-Factor Solution to the Questionnaire of Cognitive and Affective Empathy in a French Population of Patients With Schizophrenia Spectrum Disorders
Front. Psychiatry. 2019-10-25. 10
10.3389/fpsyt.2019.00751 -
Sexual dysfunctions are associated with major depression, chronic inflammation and anticholinergic consumption in the real-world schizophrenia FACE-SZ national cohort
Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2019-08-01. 94 : 109654.
10.1016/j.pnpbp.2019.109654 -
Machine learning for predicting psychotic relapse at 2 years in schizophrenia in the national FACE-SZ cohort
Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2019-06-01. 92 : 8-18.
10.1016/j.pnpbp.2018.12.005 -
Relationship between childhood trauma and level of insight in schizophrenia: A path-analysis in the national FACE-SZ dataset
Schizophrenia Research. 2019-06-01. 208 : 90-96.
10.1016/j.schres.2019.04.006 -
Validation and refinement of the clinical staging model in a French cohort of outpatient with schizophrenia (FACE-SZ)
Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2019-06-01. 92 : 226-234.
10.1016/j.pnpbp.2019.01.003 -
Towards an improved access to psychiatric rehabilitation: availability and effectiveness at 1-year follow-up of psychoeducation, cognitive remediation therapy, cognitive behaviour therapy and social skills training in the FondaMental Advanced Centers of Expertise-Schizophrenia (FACE-SZ) national cohort
Eur Arch Psychiatry Clin Neurosci. 2019-04-08. 269(5) : 599-610.
10.1007/s00406-019-01001-4 -
A multi-dimensional approach to the relationship between insight and aggressiveness in schizophrenia: Findings from the FACE-SZ cohort
Schizophrenia Research. 2019-02-01. 204 : 38-45.
10.1016/j.schres.2018.07.029 -
Inflammatory DEpression Advances in Schizophrenia (IDEAS): A precision medicine approach of the national FACE-SZ cohort
Journal of Affective Disorders. 2019-02-01. 245 : 468-474.
10.1016/j.jad.2018.11.004 -
The 10-year findings from the FondaMental Academic Center of Expertise for Schizophrenia (FACE-SZ): Review and recommendations for clinical practice,Centres Experts Schizophrénie, un outil pour le soin et la recherche : retour sur 10 ans d’expérience
L'Encéphale. 2019-02-01. 45(1) : 9-14.
10.1016/j.encep.2018.07.007 -
Prevalence of and Risk Factors for Extrapyramidal Side Effects of Antipsychotics: Results From the National FACE-SZ Cohort.
J. Clin. Psychiatry. 2019-01-08. 80(1)
10.4088/jcp.18m12246 -
Hypovitaminosis D is associated with depression and anxiety in schizophrenia: Results from the national FACE-SZ cohort.
Psychiatry Research. 2018-12-01. 270 : 104-110.
10.1016/j.psychres.2018.09.024 -
Latent toxoplasma infection in real-world schizophrenia: Results from the national FACE-SZ cohort
Schizophrenia Research. 2018-11-01. 201 : 373-380.
10.1016/j.schres.2018.05.007 -
Psychiatric disability as mediator of the neurocognition-functioning link in schizophrenia spectrum disorders: SEM analysis using the Evaluation of Cognitive Processes involved in Disability in Schizophrenia (ECPDS) scale
Schizophrenia Research. 2018-11-01. 201 : 196-203.
10.1016/j.schres.2018.06.021 -
Metabolic syndrome and illness severity predict relapse at 1-year follow-up in schizophrenia: The FACE-SZ cohort
J. Clin. Psychiatry. 2018-09-18. 79(6)
10.4088/JCP.17m12007 -
Self-reported pain in patients with schizophrenia. Results from the national first-step FACE-SZ cohort.
Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2018-07-01. 85 : 62-68.
10.1016/j.pnpbp.2018.04.007 -
Mediation Analyses of Insight, Quality of Life, Depression, and Suicidality: Results From the FACE-SZ Cohort.
J. Clin. Psychiatry. 2018-06-27. 79(3)
10.4088/jcp.17m11638 -
Remission of depression in patients with schizophrenia and comorbid major depressive disorder: results from the FACE-SZ cohort
Br J Psychiatry. 2018-06-06. 213(2) : 464-470.
10.1192/bjp.2018.87 -
Chronic low-grade peripheral inflammation is associated with ultra resistant schizophrenia. Results from the FACE-SZ cohort
Eur Arch Psychiatry Clin Neurosci. 2018-05-28. 269(8) : 985-992.
10.1007/s00406-018-0908-0 -
Influence of Venus and Mars in the cognitive sky of schizophrenia. Results from the first-step national FACE-SZ cohort.
Schizophrenia Research. 2018-05-01. 195 : 357-365.
10.1016/j.schres.2017.09.027 -
Risk factors for increased duration of untreated psychosis. Results from the FACE-SZ dataset.
Schizophrenia Research. 2018-05-01. 195 : 529-533.
10.1016/j.schres.2017.08.058 -
Evaluation of adherence patterns in schizophrenia using electronic monitoring (MEMS®): A six-month post-discharge prospective study.
Schizophrenia Research. 2018-03-01. 193 : 114-118.
10.1016/j.schres.2017.06.026 -
Tobacco smoking is associated with antipsychotic medication, physical aggressiveness, and alcohol use disorder in schizophrenia: results from the FACE-SZ national cohort.
Eur Arch Psychiatry Clin Neurosci. 2018-02-02. 269(4) : 449-457.
10.1007/s00406-018-0873-7 -
Factors associated with direct health care costs in schizophrenia: Results from the FACE-SZ French dataset.
European Neuropsychopharmacology. 2018-01-01. 28(1) : 24-36.
10.1016/j.euroneuro.2017.11.020 -
Relationships between low-grade peripheral inflammation and psychotropic drugs in schizophrenia: results from the national FACE-SZ cohort.
Eur Arch Psychiatry Clin Neurosci. 2017-11-10. 268(6) : 541-553.
10.1007/s00406-017-0847-1 -
Medication adherence in schizophrenia: The role of insight, therapeutic alliance and perceived trauma associated with psychiatric care.
Psychiatry Research. 2017-11-01. 257 : 315-321.
10.1016/j.psychres.2017.07.063 -
Predictors of rapid high weight gain in schizophrenia: Longitudinal analysis of the French FACE-SZ cohort.
Journal of Psychiatric Research. 2017-11-01. 94 : 62-69.
10.1016/j.jpsychires.2017.06.008 -
Cigarette smoking and schizophrenia: a specific clinical and therapeutic profile? Results from the FACE-Schizophrenia cohort.
Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2017-10-01. 79 : 332-339.
10.1016/j.pnpbp.2017.06.026 -
Advanced paternal age is associated with earlier schizophrenia onset in offspring. Results from the national multicentric FACE-SZ cohort.
Psychiatry Research. 2017-08-01. 254 : 218-223.
10.1016/j.psychres.2017.04.002 -
Childhood trauma, depression and negative symptoms are independently associated with impaired quality of life in schizophrenia. Results from the national FACE-SZ cohort.
Schizophrenia Research. 2017-07-01. 185 : 173-181.
10.1016/j.schres.2016.12.021 -
Childhood trauma, depression and negative symptoms are independently associated with impaired quality of life in schizophrenia. Results from the national FACE-SZ cohort
Schizophrenia Research. 2017-07-01. 185 : 173-181.
10.1016/j.schres.2016.12.021 -
Nicotine dependence is associated with depression and childhood trauma in smokers with schizophrenia: results from the FACE-SZ dataset.
Eur Arch Psychiatry Clin Neurosci. 2017-04-07. 267(6) : 567-577.
10.1007/s00406-017-0779-9 -
Validation study of the Medication Adherence Rating Scale. Results from the FACE-SZ national dataset.
Schizophrenia Research. 2017-04-01. 182 : 84-89.
10.1016/j.schres.2016.10.023 -
Benzodiazepine long-term administration is associated with impaired attention/working memory in schizophrenia: results from the national multicentre FACE-SZ data set.
Eur Arch Psychiatry Clin Neurosci. 2017-03-27. 268(1) : 17-26.
10.1007/s00406-017-0787-9 -
Chronic low-grade peripheral inflammation is associated with severe nicotine dependence in schizophrenia: results from the national multicentric FACE-SZ cohort.
Eur Arch Psychiatry Clin Neurosci. 2017-02-25. 267(5) : 465-472.
10.1007/s00406-017-0771-4 -
Hallucinations in schizophrenia and Parkinson’s disease: an analysis of sensory modalities involved and the repercussion on patients.
Sci Rep. 2016-12-01. 6(1)
10.1038/srep38152 -
Determination of Adherence Profiles in Schizophrenia Using Self-Reported Adherence: Results From the FACE-SZ Dataset.
J. Clin. Psychiatry. 2016-09-28. 77(09) : e1130-e1136.
10.4088/jcp.15m10115 -
Differential effects of childhood trauma and cannabis use disorders in patients suffering from schizophrenia.
Schizophrenia Research. 2016-08-01. 175(1-3) : 161-167.
10.1016/j.schres.2016.04.042 -
Chronic Peripheral Inflammation is Associated With Cognitive Impairment in Schizophrenia: Results From the Multicentric FACE-SZ Dataset.
SCHBUL. 2016-05-03. 42(5) : 1290-1302.
10.1093/schbul/sbw029 -
Medication and aggressiveness in real-world schizophrenia. Results from the FACE-SZ dataset.
Psychopharmacology. 2015-12-03. 233(4) : 571-578.
10.1007/s00213-015-4167-8 -
Akathisia: Prevalence and risk factors in a community-dwelling sample of patients with schizophrenia. Results from the FACE-SZ dataset
Schizophrenia Research. 2015-12-01. 169(1-3) : 255-261.
10.1016/j.schres.2015.10.040 -
Metabolic syndrome, abdominal obesity and hyperuricemia in schizophrenia: Results from the FACE-SZ cohort
Schizophrenia Research. 2015-10-01. 168(1-2) : 388-394.
10.1016/j.schres.2015.07.047 -
Medication adherence in patients with psychotic disorders: An observational survey involving patients before they switch to long-acting injectable risperidone
PPA. 2015-09-01. : 1333.
10.2147/PPA.S89748 -
A National network of schizophrenia expert centres: An innovative tool to bridge the research-practice gap
Eur. psychiatr.. 2015-06-10. 30(6) : 728-735.
10.1016/j.eurpsy.2015.05.004 -
Impulsive aggressive obsessions following cerebellar strokes: a case study.
J Neurol. 2015-06-06. 262(7) : 1775-1776.
10.1007/s00415-015-7804-6 -
Validation of a Psycho-Sensory hAllucinations Scale (PSAS) in schizophrenia and Parkinson’s disease.
Schizophrenia Research. 2015-02-01. 161(2-3) : 269-276.
10.1016/j.schres.2014.11.010 -
Depression in schizophrenia: the influence of the different dimensions of insight.
Psychiatry Research. 2014-04-01. 216(1) : 12-16.
10.1016/j.psychres.2014.01.039 -
Depression in schizophrenia: the influence of the different dimensions of insight.
Psychiatry Research. 2014-04-01. 216(1) : 12-16.
10.1016/j.psychres.2014.01.039 -
Factors predictive of medication nonadherence after renal transplantation: a French observational study.
Transplantation Journal. 2013-01-01. 95(2) : 326-332.
10.1097/TP.0b013e318271d7c1 -
Factors predictive of medication nonadherence after renal transplantation: a French observational study.
Transplantation Journal. 2013-01-01. 95(2) : 326-332.
10.1097/TP.0b013e318271d7c1 -
The influence of therapeutic alliance and insight on medication adherence in schizophrenia.
Nordic Journal of Psychiatry. 2011-08-10. 66(1) : 49-54.
10.3109/08039488.2011.598556 -
The influence of therapeutic alliance and insight on medication adherence in schizophrenia.
Nordic Journal of Psychiatry. 2011-08-10. 66(1) : 49-54.
10.3109/08039488.2011.598556 -
Insight and schizophrenia: What roles in the suicide risk?,Insight et schizophrénie: quels rôles dans le risque suicidaire?
Annales Médico-psychologiques, revue psychiatrique. 2011-08-01. 169(7) : 426-428.
10.1016/j.amp.2011.06.008 -
Insight and schizophrenia: What roles in the suicide risk?,Insight et schizophrénie: quels rôles dans le risque suicidaire?
Annales Médico-psychologiques, revue psychiatrique. 2011-08-01. 169(7) : 426-428.
10.1016/j.amp.2011.06.008 -
Amphiphilic properties of dumbbell-shaped inorganic-organic-inorganic molecular hybrid materials in solution and at an interface.
Langmuir. 2011-06-30. 27(15) : 9193-9202.
10.1021/la2013914 -
Amphiphilic properties of dumbbell-shaped inorganic-organic-inorganic molecular hybrid materials in solution and at an interface.
Langmuir. 2011-06-30. 27(15) : 9193-9202.
10.1021/la2013914 -
The 4-Point ordinal Alliance Self-report: a self-report questionnaire for assessing therapeutic relationships in routine mental health.
Comprehensive Psychiatry. 2009-03-01. 50(2) : 181-185.
10.1016/j.comppsych.2008.06.010 -
The 4-Point ordinal Alliance Self-report: a self-report questionnaire for assessing therapeutic relationships in routine mental health.
Comprehensive Psychiatry. 2009-03-01. 50(2) : 181-185.
10.1016/j.comppsych.2008.06.010 -
Development of a targeted, insight-based psycho-educational program for patients with schizophrenia,Développement d’un programme psycho-éducatif ciblé sur l’insight pour les patients souffrant de schizophrénie
L'information psychiatrique. 2008-12-01. Volume 84(10) : 937-939.
10.1684/ipe.2008.0414 -
Development of a targeted, insight-based psycho-educational program for patients with schizophrenia,Développement d’un programme psycho-éducatif ciblé sur l’insight pour les patients souffrant de schizophrénie
L'information psychiatrique. 2008-12-01. Volume 84(10) : 937-939.
10.1684/ipe.2008.0414 -
Efficiency and safety of oxcarbazepine in mood disorders: a naturalistic study exploring the interest of plasma dosages.
Eur. psychiatr.. 2008-09-01. 23(6) : 409-412.
10.1016/j.eurpsy.2008.05.003 -
Efficiency and safety of oxcarbazepine in mood disorders: A naturalistic study exploring the interest of plasma dosages
Eur. psychiatr.. 2008-09-01. 23(6) : 409-412.
10.1016/j.eurpsy.2008.05.003 -
Efficiency and safety of oxcarbazepine in mood disorders: a naturalistic study exploring the interest of plasma dosages.
Eur. psychiatr.. 2008-09-01. 23(6) : 409-412.
10.1016/j.eurpsy.2008.05.003 -
Towards a reconceptualization of mixed states, based on an emotional-reactivity dimensional model.
Journal of Affective Disorders. 2007-08-01. 101(1-3) : 35-41.
10.1016/j.jad.2006.10.027 -
Towards a reconceptualization of mixed states, based on an emotional-reactivity dimensional model.
Journal of Affective Disorders. 2007-08-01. 101(1-3) : 35-41.
10.1016/j.jad.2006.10.027 -
Pattern of health service utilization and predictors of readmission after a first admission for psychosis: a 2-year follow-up study.
Acta Psychiatr Scand. 2006-04-01. 113(4) : 340-349.
10.1111/j.1600-0447.2005.00694.x -
Pattern of health service utilization and predictors of readmission after a first admission for psychosis: a 2-year follow-up study.
Acta Psychiatr Scand. 2006-04-01. 113(4) : 340-349.
10.1111/j.1600-0447.2005.00694.x -
Prepartum chronic ultramild stress increases corticosterone and estradiol levels in gestating mice: implications for postpartum depressive disorders.
Psychiatry Research. 2005-11-01. 137(1-2) : 123-130.
10.1016/j.psychres.2005.07.020 -
Prepartum chronic ultramild stress increases corticosterone and estradiol levels in gestating mice: implications for postpartum depressive disorders.
Psychiatry Research. 2005-11-01. 137(1-2) : 123-130.
10.1016/j.psychres.2005.07.020 -
Factors influencing compulsory admission in first-admitted subjects with psychosis
Soc Psychiatry Psychiatr Epidemiol. 2004-06-01. 39(10) : 804-809.
10.1007/s00127-004-0826-5 -
DSM-IV mental disorders and neurological complications in children and adolescents with human immunodeficiency virus type 1 infection (HIV-1).
Eur. psychiatr.. 2004-05-01. 19(3) : 182-184.
10.1016/j.eurpsy.2003.06.009 -
Pathways to care of first-admitted subjects with psychosis in South-Western France.
Psychol. Med.. 2004-01-28. 34(2) : 267-276.
10.1017/S003329170300120X -
Pathways to care of first-admitted subjects with psychosis in South-Western France
Psychol. Med.. 2004-01-28. 34(2) : 267-276.
10.1017/S003329170300120X